Injuries & OrthopedicsAn evidence-graded review of the peptides marketed for wrist sprains, tenosynovitis, TFCC tears and carpal tunnel syndrome. The honest 2026 verdict: no human RCT — indeed essentially no human data of any kind — exists; the case is entirely preclinical (rat tendon and sciatic-nerve models), and conventional care has the far stronger human evidence.
Injuries & Orthopedics12 MIN READ
Injuries & OrthopedicsTendon is the single best-studied musculoskeletal target for repair peptides — yet no human RCT exists for any peptide in any tendinopathy. We rank BPC-157, TB-500/thymosin β-4 and GHK-Cu strictly by the real evidence.
Injuries & Orthopedics12 MIN READ
Injuries & OrthopedicsA clinical, evidence-first look at the peptides pitched for rotator-cuff tears, labral injury and shoulder tendinopathy — BPC-157, TB-500/thymosin β-4, and GHK-Cu — and why all three are graded C (preclinical only) for the shoulder.
Injuries & Orthopedics11 MIN READ
Injuries & OrthopedicsAn evidence-graded look at the peptides marketed for rotator-cuff tears and repair recovery — BPC-157, TB-500/Thymosin β4 and GHK-Cu — separating a single unpublished rat abstract and animal mechanism from anything resembling human proof.
Injuries & Orthopedics12 MIN READ
Injuries & OrthopedicsAn evidence-graded review of the peptides marketed for whiplash and neck soft-tissue injury. The honest 2026 verdict: there is no human evidence — no RCT, cohort, or registered trial — for any peptide in the cervical spine; the strongest case tops out at rat ligament and tendon models.
Injuries & Orthopedics12 MIN READ
Injuries & OrthopedicsAn evidence-graded review of the peptides marketed for meniscus tears, ligament sprains, tendinopathy and cartilage wear. The honest 2026 verdict: no peptide has a placebo-controlled human knee trial — the strongest case is preclinical (rat surgery models) plus one uncontrolled human case series.
Injuries & Orthopedics12 MIN READ
Injuries & OrthopedicsAn evidence-graded review of the peptides marketed to 'injury-proof' tendons and ligaments. The honest 2026 verdict: prevention is the single most speculative claim in the peptide literature — no human prevention RCT, and no controlled animal prevention study, exists for any candidate.
Injuries & Orthopedics13 MIN READ
Injuries & OrthopedicsAn evidence-graded review of the peptides marketed for hip labral tears, femoroacetabular impingement, gluteal tendinopathy (GTPS) and hip bursitis. The honest 2026 verdict: no peptide has a human hip trial — the evidence tops out at animal models, while exercise and PRP hold the real human RCT data.
Injuries & Orthopedics12 MIN READ
Injuries & OrthopedicsA clinical, evidence-first look at the peptides pitched for lateral and medial epicondylitis — BPC-157 and TB-500/thymosin β-4 — and why both are graded C (preclinical only) for the elbow.
Injuries & Orthopedics10 MIN READ
Injuries & OrthopedicsAn evidence-graded review of the peptides marketed for ankle sprains, ATFL tears and Achilles injury. The honest 2026 verdict: no human RCT exists; the strongest case is preclinical (rat Achilles models), and PRP — not a peptide — has the better human ankle evidence.
Injuries & Orthopedics12 MIN READ
Peptide EncyclopediaA clinical monograph on TB-500 — the synthetic thymosin β4 fragment (Ac-LKKTETQ) marketed for tendon, muscle and tissue repair. Strong preclinical biology, no human efficacy RCT of the fragment, and an unsettled 2026 legal status.
Peptide Encyclopedia11 MIN READ
Peptide EncyclopediaA clinical monograph on Pentadeca Arginate (PDA) — the L-arginine salt of BPC-157 marketed for tendon, gut and wound healing. Zero PDA-specific studies, borrowed preclinical data, and an unsettled 2026 legal status.
Peptide Encyclopedia11 MIN READ
Peptide EncyclopediaA clinical monograph on BPC-157 — the stable gastric pentadecapeptide marketed for tendon, gut and wound healing. Deep preclinical data, no completed human RCT, and an unsettled 2026 legal status.
Peptide Encyclopedia11 MIN READ